--- a
+++ b/clusters/3009knumclusters/clust_222.txt
@@ -0,0 +1,801 @@
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI4736 or previous toxicity attributed to MEDI4736 or other PD-1 or PD-L1 directed therapy that led to drug discontinuation
+History of allergic reaction attributed to compounds of similar chemical or biologic composition to the MEK inhibitor, trametinib
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel and/or both platinum-based chemotherapy agents are excluded; patient must be able to receive at least one of the two proposed chemotherapy regimens
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or other agents used in study, or history of severe hypersensitivity reaction to any monoclonal antibody
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib or bevacizumab
+Patients with a history of allergic reactions attributed to compounds of similar composition, including macrolide and ketolide antibiotics, temsirolimus/other mTOR inhibitors, temozolomide or irinotecan are not eligible
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to LY2606368 or to its formulation are not eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) and/or rhIL-12 or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and ramucirumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs (e.g. cisplatin)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition as the study agents
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
+Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
+Patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or other agents used in the study
+Patients must NOT have a history of allergic reactions attributed to compounds of similar chemical or biochemical composition to cisplatin, carboplatin, etoposide, temozolomide or capecitabine
+History of allergic reactions attributed to compounds of chemical or biologic composition similar to palbociclib.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and atezolizumab; patients with a known hypersensitivity to olaparib or any of the excipients of the product
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to hetIL-15.
+History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to the taselisib drug formulation or other agents used in this study
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib are not eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to phenelzine or other monoamine oxidase inhibitors
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or trastuzumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, decitabine or SGI-110
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to afatinib or docetaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to GM-CSF
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to sotatercept, lenalidomide, pomalidomide, or dexamethasone
+Patients who have any history of allergic reaction(s) attributed to compounds of similar composition to temozolomide, pazopanib, their metabolites, or any component of their formulation are NOT eligible for participation
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ficlatuzumab or other agents used in study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab and trebananib including history of allergic reactions to bacterially produced proteins
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PT2385 are ineligible
+Subject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to bavituximab
+Patients with history of allergic reactions attributed to compounds of similar composition to pazopanib, irinotecan, or temozolomide are not eligible
+Patients may not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib (including abemaciclib)
+Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, everolimus or exemestane
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ramucirumab
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib are not eligible; AND/OR patients who have had prior exposure to compounds of similar chemical or biologic composition to palbociclib are not eligible hypersensitivity to any component of palbociclib are not eligible for participation
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ribociclib, T-DM1 (Cohort A)) and/or trastuzumab (Cohorts B and C) and/or fulvestrant (Cohort C)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PLX3397 or sirolimus
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or carboplatin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-P.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinib
+History of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 or paclitaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib (BMN 673) or other agents used in study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, nab-paclitaxel, or other agents used in the study; previous grade 1 or 2 allergic reaction to cetuximab is permissible
+History of allergic reactions/hypersensitivity attributed to compounds of similar chemical or biologic composition to tamoxifen, anastrozole, or fulvestrant or any of their ingredients
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus
+History of allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition to anastrozole or letrozole
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to liposomal cytarabine or other agents used in study inclusive of known allergy to polyethylene glycol
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)
+Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin and/or rituximab
+Known allergy to any of the study agents or to compounds of similar chemical or biologic composition are excluded (including other somatostatin analogs)
+History of allergic reactions or adverse reactions (e.g., wound dehiscence) attributed to compounds of similar chemical or biologic composition to PLG or known hypersensitivity to GM-CSF, CPG or PLG
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991or other agents used in the study
+Known history of allergic reactions attributed to compounds of similar chemical or biologic composition to fenretinide, such as 13-cis-retinoic acid, retinol, or all-trans-retinoic acid
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib or LY3300054.
+Subjects with a history of hypersensitivity to compounds of similar biologic composition to atezolizumab or any constituent of the product
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MCS110, dabrafenib, or trametinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab or nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to BVD-523
+Subjects with a history of hypersensitivity to compounds of similar biologic composition to atezolizumab or any constituent of the product
+History of allergic reactions attributed to compounds, or any of its excipients, of similar chemical or biologic composition to osimertinib or selumetinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclib
+History of allergic reactions attributed to compounds of similar chemical composition to chemotherapy to be used in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to daratumumab
+Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab
+Women with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Tamoxifen.
+EXPANDED ACCESS COHORT: History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or binimetinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide (only for arm B)
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to monoclonal antibody treatment, any components used in the ramucirumab drug product (DP) preparation, irinotecan, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical composition to SY-1365
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to gefitinib or osimertinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to LY3022855, vemurafenib, or cobimetinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to apalutamide or docetaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or previous toxicity attributed to pembrolizumab or other PD-1 directed therapy that led to permanent drug discontinuation
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib or olaparib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or ganitumab or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or cisplatin
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970 or irinotecan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib (XL184)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or gemcitabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 (onalespib)
+Patents with history of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to platinum based chemotherapy
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to vemurafenib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or IMGN853
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or venetoclax
+Known hypersensitivity to MK-3475 (pembrolizumab) or history of allergic reactions to compounds of similar chemical or biologic composition to anti-PD1 or PD-L1 antibodies or entinostat
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to HMAs
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to merestinib
+Participant has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ACTOplus Met XR
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ixazomib or lenalidomide
+Participant with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of retinoids
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib.
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab are not eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to mifepristone or paclitaxel/nab-paclitaxel; patients with a history of mild infusion reactions with paclitaxel who were able to continue to receive paclitaxel with corticosteroid premedication will be eligible to participate, as these cases were likely related to cremaphor and not paclitaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents (cyclophosphamide, busulfan, pentostatin, sirolimus, MMF, granulocyte-colony stimulating factor [G-CSF]) used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in this study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to defactinib, pembrolizumab, gemcitabine, or other agents used in the study
+Subject has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PROSTVAC or ipilimumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to sertraline
+Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib or everolimus
+History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e. gentamicin)
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or other agents (R-CHOP) used in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to INC280; excipients in the current formulation include microcrystalline cellulose, mannitol, sodium starch glycolate, magnesium stearate and colloidal silicon dioxide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or TMZ
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX-200 or other agents used in the study (e.g., imidazoles, quinolones)
+Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or docetaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or lenalidomide agents used in study, such as bortezomib or thalidomide, in addition to patients with known allergy to sulfobutyl ether beta-cyclodextrin (Captisol)
+Known hypersensitivity or allergic reactions attributed to any compounds of similar chemical or biologic composition to the study medication, such as recombinant IL-12 or other monoclonal antibodies
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Combotox or other agents used in study agents
+History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, anetumab ravtansine or paclitaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MTX110 or gadolinium.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib, mirvetuximab soravtansine or monoclonal antibodies
+History of allergic reactions attributed to compound of similar chemical or biologic composition to the agents used in this study.
+History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to olaparib or its excipients
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide, CRLX101, or other agents used in study.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the regimen
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents to be used in the cohort the subject will be enrolled into
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel or avelumab, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0 grade >= 3)
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ADI-PEG 20, gemcitabine, pegylated compounds, or other agents used in the study
+History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells
+Hypersensitivity to chemotherapy or history of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab, ibrutinib, ICE, Ave, or Uto
+Has a history of allergic reactions attributed to the study treatments (AZD9150 or durvalumab), assigned chemotherapy agents, their compounds, or agents of similar chemical or biologic composition (e.g., antibody therapeutics)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients.
+History of significant allergic reactions attributed to compounds of similar composition to SD-101 or BMS-986178
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to apatinib or pembrolizumab
+COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study
+COHORT 2: TRIPLE NEGATIVE BREAST CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study
+COHORT 3: ENDOMETRIAL CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, cisplatin (for cohort 1), or cetuximab (for cohort 2)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents on this trial
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study vaccine components and any of the chemotherapy drugs (docetaxel, carboplatin, trastuzumab, pertuzumab)
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat, ruxolitinib, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide and blinatumomab or other agents used in study
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to anti-LAG-3, anti-CD137, and anti-PD1 are ineligible; the investigator brochures can be referenced for more information
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent or accompanying supportive medications.
+The patient has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab and/or nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, carboplatin and paclitaxel or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to EGF816 or gefitinib
+Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to IACS-010759.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to leuprolide acetate, abiraterone acetate, prednisone or apalutamide or other agents used in the study.
+History of known immediate or delayed hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to INCB039110, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO).
+History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to avelumab or other agents used in the study (or monoclonal antibodies)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Vicinium or durvalumab or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab unless felt to be in the best interests of the patient in the opinion of the investigator
+Patient must not have a history of allergic reactions like anaphylaxis attributed to compounds of similar chemical or biologic composition to meclizine such as antihistamine drugs.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to fostamatinib or paclitaxel; patients who are able to tolerate paclitaxel on a desensitization protocol will be allowed
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or mifepristone
+History of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AZD8186 or docetaxel or to docetaxel itself
+Patients with a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or T-DM1
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel or carboplatin
+Known severe hypersensitivity to selumetinib or olaparib, their comparators, or combination medications or any excipient of these medicinal products, or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or olaparib, or their comparator
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to blinatumomab or pembrolizumab or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan, other topoisomerase inhibitors or gadolinium compounds
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to HMAs
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to lamivudine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to zydelig
+History of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab (anti-EGFR).
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to anetumab ravtansine or MK-3475 (pembrolizumab)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, carboplatin, pembrolizumab, or other agents used in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel including to other drugs formulated in cremophor(R) EL (polyoxyethylated castor oil)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, topotecan, gadolinium, or lipids
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide are not eligible
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to denosumab are not eligible (i.e. same class of drugs) (Note: prior bisphosphonates are allowed; patients could have received bisphosphonates or be bisphosphonate-naive; patients who were previously on bisphosphonates can be enrolled in the study, as long as they have a wash-out period of 2 weeks prior to registration)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy agents in this study (if necessary)
+Known hypersensitivity to poziotinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to poziotinib
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to mistletoe
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-DOTA-tyr3-octreotide, Octreoscan, 68Ga-octreotide, or 131I-MIBG
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to clarithromycin or taxanes
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1127 (varlilumab) and/or nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
+History of allergic reactions attributed to compounds of chemical or biologic composition similar to palbociclib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib or nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or abiraterone
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or pemetrexed and cisplatin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab are not eligible; known hypersensitivity to any excipients of pembrolizumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, decitabine or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to hydroxychloroquine or received HCQ in the past six months
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to fosbretabulin
+Hypersensitivity to BV or history of allergic reaction attributed to compounds of similar chemical or biologic composition of BV
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat or decitabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to IL-2
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib and blinatumomab or other agents used in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin
+Known hypersensitivity to compounds of similar chemical composition to BMX-001
+Known allergy to compounds of similar chemical or biologic composition to nivolumab
+Has a history of allergic reactions attributed to the study treatments (AZD9150 or MEDI4736), their compounds, or agents of similar chemical or biologic composition (eg, antibody therapeutics)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to TVB-2640
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in study
+History of allergic reactions attributed to compounds of chemical or biologic composition similar to interferons or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide and/or TG02
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or indomethacin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab, cisplatin, carboplatin, or etoposide
+Patients with known allergy to eggs or to compounds with a similar chemical or biologic composition to PROSTVAC or nivolumab
+History of allergic reactions attributed to compounds of similar composition to SD-101 or ibrutinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to daunorubicin
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, letrozole, trastuzumab, any other aromatase inhibitor, any other monoclonal antibody, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, carboplatin or cisplatin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or talazoparib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab including any history of severe allergic reactions to monoclonal antibody therapy
+Patients with a history of allergic reactions attributed to or intolerance to compounds of similar chemical or biologic composition to either CB-839 or capecitabine; if capecitabine has been received previously, must have tolerated at least an equivalent dose to the dose to be administered at their assigned dose level
+Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin and pemetrexed
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor
+History of allergic reactions attributed to compounds of similar chemical or biological composition to rebastinib or other agents used in the study (e.g., Cremophor)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to blinatumomab
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab are not eligible AND/OR patients who have had prior exposure to compounds of similar chemical or biologic composition to pembrolizumab are not eligible
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BCG are not eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to abiraterone or PDMX1001/niclosamide
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI3475 are not eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cesium 131 or other agents used in this study
+History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to lenvatinib and/or paclitaxel
+History of allergic reactions attributed to fluorouracil (5-FU), leucovorin, irinotecan or oxaliplatin or to compounds of similar chemical or biologic composition
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent or other agents used in the study
+PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: History of allergic reactions attributed to compounds of similar chemical or biologic composition to CRLX101 and/or olaparib or other agents used in study
+History of allergic reaction to compounds of similar chemical or biologic composition to cytarabine
+Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to IRX5183
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or irinotecan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib and brentuximab vedotin (BV)
+History of severe allergic reactions attributed to compounds of similar chemical or biologic composition as obinutuzumab or ibrutinib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ramucirumab or nab-paclitaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib
+Known allergy to compounds of similar chemical or biologic composition to nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to methotrexate, vinblastine, doxorubicin or cisplatin or other agents used in the study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib, temozolomide, or dacarbazine
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to DHEA or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine or bevacizumab
+History of allergic reactions attributed to thalidomide, lenalidomide, or other compounds of similar chemical or biologic composition to pomalidomide or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)
+History of allergic reactions attributed to Noni or other compounds of similar chemical or biologic composition to Noni, or the inactive components present in Noni capsules; uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any psychological, familial, sociological or other concomitant condition that would not allow adequate compliance with the study protocol
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or other agents used in the study
+A history of allergic reaction attributed to compounds of similar chemical or biologic composition to fluorouracil (5FU), oxaliplatin, or leucovorin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or bortezomib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, methotrexate, gemcitabine or other agents used during the study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BVD-523, gemcitabine, nab-paclitaxel, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to dexrazoxane or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab, paclitaxel or carboplatin
+Subjects with a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to DS3032b
+PHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or tremelimumab, or other agents used in study
+PHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or tremelimumab, or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to methoxyamine or to pemetrexed or cisplatin
+History of allergic reactions, intolerance or hypersensitivity attributed to compounds of similar chemical or biologic composition to TRC105 and/or everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological component
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to leflunomide or cholestyramine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in study
+PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736, olaparib, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma
+PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma
+History of allergic reaction attributed to compound(s) of similar chemical or biologic composition as ARQ 092, carboplatin, paclitaxel, or anastrozole
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to indoximod, docetaxel, or other agents used in the study.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the pre- or post-transplant regimen
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABRAXANE or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed
+Patients with history of allergic reactions attributed to compounds of similar chemical; or biologic composition to vorinostat or temsirolimus are not eligible
+History of hypersensitivity reaction specifically attributed to compounds of similar chemical or biologic composition to 5-FU, leucovorin, capecitabine or bevacizumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in the study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to mitomycin C or other agents used in the study
+Prior allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or trametinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to basiliximab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or metformin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to VOR or HCQ
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to nintedanib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients
+History of allergic reactions attributed to Flagyl (metronidazole), which has a chemical structure similar to EF5
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or ziv-aflibercept
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine and or busulfan or other agents used in this study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or carboplatin
+History of known immediate or delayed hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to AT13387, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to etoposide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in this study
+History of allergic reactions attributed to compounds of similar biologic composition to M032 or to IL-12
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to propranolol
+History of allergic reactions to compounds of similar composition to either CDX-301 or poly-ICLC
+History of prior allergic reactions attributed to compounds of similar chemical or biologic composition as capecitabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, oxaliplatin, irinotecan or gemcitabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, docetaxel, vorinostat, or granulocyte colony-stimulating factor (G-CSF)
+History of allergic reactions attributed to compounds of similar chemical composition agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to anakinra or other agents used in study; known hypersensitivity to Chinese hamster ovary (CHO)-cell derived biologics or any components of anakinra
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to DOPC, Magnevist, or fluorodeoxyglucose (FDG)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin for patients who will receive chemotherapy
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the experimental agents or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9291 (osimertinib) or bevacizumab
+No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, lomustine, vincristine (vincristine sulfate) or cyclophosphamide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin
+EXCLUSION CRITERIA FOR REGISTRATION: history of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin
+History of allergic reactions attributed to compounds of similar chemical or biological composition to Valproic Acid
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and durvalumab or previous toxicity attributed to durvalumab or other PD-1 or PD-L1 directed therapy that led to drug discontinuation
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to TCN-PM
+History of severe allergic reactions or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to STA-9090 (eg. Polyethylene glycol [PEG] 300 and Polysorbate 80)
+History of allergic reactions to compounds of similar chemical or biologic composition to talactoferrin or the chemotherapy drugs
+History of allergic reactions attributed to compounds of similar chemical composition to IHL-305
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cenersen.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib and/or nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to agent(s) or other agents used in study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorolanib, nivolumab, or pembrolizumab (as applicable), any monoclonal antibody, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to CPI-613 or docetaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil or imiquimod
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to CPI-613
+History of allergic reactions attributed to compounds of similar chemical or biologic composition;
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs; patients who have previously received either clofarabine or bortezomib will be excluded
+Patients with known hypersensitivity to nintedanib or 5-azacitidine or who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nintedanib or 5-azacitidine are not eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenvatinib
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BMS-813160, nivolumab, gemcitabine, paclitaxel, nab-paclitaxel, or other agents used in the study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to poly-ICLC or other agents used in the study.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab or any excipient or any egg products
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MCS110, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or PDMX1001/niclosamide
+A history of allergic reactions or significant toxicity attributed to compounds of similar chemical or biologic composition to anti-CD20 mAbs, anti-PD-1 mAbs, or TLR agonists.
+Participants who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to birinapant or its constituents
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to regorafenib or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to WP1066
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX970), cisplatin, or gemcitabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or sorafenib
+Patients with a history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 are ineligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nelfinavir
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to measles virus vaccination
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and AT13387 used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to XL184
+Subjects with history of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 or carfilzomib, lenalidomide, or dexamethasone
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BAL101553 are ineligible
+History of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in this study
+History of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PLX3397 or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to quinacrine, capecitabine or fluorouracil
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or vistusertib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to tazemetostat
+Patients with a known hypersensitivity to olaparib or any of the excipients of the product; history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102 or TMZ
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib, carboplatin, cisplatin, or etoposide
+History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to either paclitaxel or ricolinostat; patients who require administration of paclitaxel through a desensitization procedure are not eligible for this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib and MM-398; if patients have a history of allergic reactions to compounds resembling MM-398, they will be excluded from participating in the FMX MRI study, if applicable
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970, carboplatin, gemcitabine or to these specific compounds
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib (difficulty breathing, lip swelling, itching or rash)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 and ziv-aflibercept
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or cisplatinum or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to briciclib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs (e.g. cisplatin, paclitaxel)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or belinostat
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
+History of allergic reactions to compounds with similar biologic or chemical composition to pembrolizumab or radium-223
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1401 or CDX-301 or poly-ICLC
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to CYT107
+History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to metformin, ritonavir or any of their ingredients
+Have history of allergic reactions attributed to compounds of similar chemical or biologic composition to taxanes (docetaxel or paclitaxel) or cyclophosphamide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to G-CSF/filgrastim (Escherichia [E] coli producing cell line), plerixafor or busulfan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ethacrynic acid or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Dex or Enza
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to G-CSF/filgrastim (E. coli producing cell line) and plerixafor
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to either 5-FU/capecitabine or interferon
+Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775
+PHASE II: Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or cyclosporine A or their excipients
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to TPI 287
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 or bevacizumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, nab-paclitaxel or enzalutamide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to HDACI, TLR-agonist, or patients with known history of pre-existing auto-immune disease
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to INCB024360, MELITAC 12.1, or other vaccine components
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or ipilimumab
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib, bortezomib or decitabine that are not easily managed
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PF-04449913
+No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, temozolomide and dacarbazine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to digoxin
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study, including Cremophor, carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar chemical or biologic composition are not eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition ipilimumab or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib, erlotinib or gemcitabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition (i.e. ethanol) to XL888 or vemurafenib (i.e., ethanol)
+Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the study
+PHASE II: Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition of decitabine, cytarabine or daunorubicin
+History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e. gentamicin)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition of those used in this study
+Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to IL-12 or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib (ABT-888) or cyclophosphamide used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (i.e. thalidomide)
+Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to lenalidomide, bortezomib and/or dexamethasone
+Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to afatinib and/or cetuximab
+History of allergic reactions attributed to compounds of similar chemical composition to afatinib
+Poor tolerability or known allergy to lenalidomide, bortezomib and/or dexamethasone or compounds that have similar chemical or biologic composition to these study drugs
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib
+Patient must have no history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or cisplatin
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991, cetuximab, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or cisplatin
+Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD 1775 (MK-1775) or gemcitabine
+History of Grade 3 or 4 allergic reactions attributed to compounds of similar chemical or biologic composition as MSC2363318A
+Subjects with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin. Compounds of similar composition include Auristatin PHE as an anti-fungal agent, Auristatin PE (TZT-1027, Soblidotin, NSC-654663) as an anti-tumor agent and Symplostatin 1 as an anti-tumor agent.
+SUB-PROTOCOL AIM A: History of allergic reactions attributed to compounds of similar chemical or biologic composition including macrolide (e.g. azithromycin, clarithromycin, dirithromycin, and erythromycin) and ketolide antibiotics
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, or other agents used in the study.
+No history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib, lenalidomide or rituximab or hypersensitivity to murine proteins or to any component of rituximab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or rapamycin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to mitomycin-C or 5-fluorouracil
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or HCQ
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to daunorubicin or cytarabine
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736 or other agents used in the study
+History of allergic reactions attributed to compounds or similar chemical or biological composition to ibrutinib
+History of allergic reactions attributable to compounds of similar chemical or biologic composition to ibrutinib or any component of pneumococcal, influenza and DTaP vaccines
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to poly-ICLC or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to mocetinostat or brentuximab vedotin
+History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, Taxotere, Xeloda, cisplatin, or irinotecan
+Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managed
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to hydroxychloroquine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dacomitinib
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or any of the components of the vaccine being administered as part of this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, bortezomib or rituximab
+History of allergic reactions attributed to compounds of similar chemical or biological composition to metformin or oxaliplatin or fluorouracil (5-FU)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 or decitabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab; prior hypersensitivity reactions to anti-CD20 therapy or anti-CD30 therapy is not an exclusion criterion
+History of allergic reaction(s) attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, irinotecan, or oxaliplatin
+History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab or other agents used in this study
+Patients who have a history of allergic reactions or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab and/or humanized antibodies are not eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or atezolizumab
+History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or lenalidomide
+Patients with a history of allergic reactions attributed to bevacizumab or to compounds of similar chemical or biologic composition to nivolumab or bevacizumab are excluded
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab, cytarabine, bendamustine or other agents used in the study
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab are not eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-JR11 as assessed from medical records
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MGE
+Subjects with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the product
+Subjects with a history of hypersensitivity to compounds of similar biologic composition to durvalumab or any constituent of the product
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 are not eligible; known hypersensitivity to any excipients of MK-3475
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to GEN-1 or other agents used in this study.
+Known allergy to any of the treatment components including a history of allergic reactions attributed to compounds of chemical or biological composition similar to olaratumab.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib and/or bazedoxifene
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PM01183 or trabectedin (Yondelis, ET-743)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9150
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to KPT-330 or other agents used in the study
+Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus or other agents used in the study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to tosedostat or capecitabine or other agents used in the study
+Participants may not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
+Patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PBI-05204 (i.e., cardiac glycoside compounds).
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, including but not limited to established allergic reaction to benzodiazepines, 5-FU (fluorouracil), leucovorin (leucovorin calcium) or oxaliplatin
+History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to IL-2
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
+Patient has a history of allergic reactions to compounds of similar chemical or biological composition to buparlisib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, cetuximab, and/or bevacizumab that led to discontinuation of those agents
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or nab-paclitaxel or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to elotuzumab or lenalidomide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or omega-3 fatty acids
+Patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475
+Prior treatment with or allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinib
+Patients must not have a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine or temsirolimus
+Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temsirolimus or perifosine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to crizotinib or enzalutamide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine and eribulin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to X-82, docetaxel, or granulocyte colony stimulating factors
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to LDE 225 or everolimus in the study or other rapamycin analogs (e.g. sirolimus, temsirolimus)
+History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or idelalisib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin or docetaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to curcumin or vitamin D or other agents used in this study
+Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managed
+History of allergic reactions or idiosyncrasy attributed to progestins or compounds of similar chemical structure to sodium cridanimod or lidocaine;
+Research participants with a history of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab
+Patients with known grade 2 or greater allergic reactions attributed to compounds of similar chemical or biologic composition to mifepristone, carboplatin, or gemcitabine are ineligible for study enrollment
+PHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
+PHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide (e.g. lenalidomide, thalidomide) or other agents used in study
+History of allergic reactions to compounds of similar chemical or biological composition to T DM1 or ONT-380, except for a history of Grade 1 or Grade 2 Infusion Related Reaction to trastuzumab which has been successfully managed.
+Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to lenalidomide, bortezomib, panobinostat and/or dexamethasone
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, azacitidine, or nivolumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib.
+Participants who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to neratinib or fulvestrant
+History of allergic reactions attributed to lenalidomide or compounds of similar chemical or biologic composition to lenalidomide including thalidomide
+PART B: History of allergic or severe reactions attributed to compounds of similar chemical or biologic composition to ponatinib
+History of allergic reactions to compounds of similar chemical composition to the study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or other drugs formulated with polysorbate 80
+History of grade 3 or 4 allergic reactions attributed to compounds of similar chemical or biologic composition to ARRY-380 or trastuzumab
+History of allergic reaction attributed to compounds of similar chemical or biologic composition to eribulin mesylate, trastuzumab or pertuzumab, which cannot be managed by premedication
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study
+Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study including dimethyl sulfoxide (DMSO)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or lenalidomide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanib or enzalutamide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or poxviral vaccines (e.g., vaccinia vaccine)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or poxviral vaccines (e.g., vaccinia vaccine)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AUY922
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to midostaurin and/or decitabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine
+Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouricil, irinotecan, oxaliplatin, or losartan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, trastuzumab, pertuzumab; patients with minor (grade 1 or 2) allergic reactions to these agents, controlled with standard supportive measures, are eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or tryptophan containing substances. This would include L-tryptophan or 5-hydroxy-tryptophan supplements. Also patients with a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80 are excluded.
+History of allergic reactions attributed to, or intolerance of, or other significant toxicity with, compounds of similar chemical or biologic composition to X-82 or everolimus
+REGISTRATION EXCLUSION CRITERIA: History of allergic reactions attributed to compounds of similar chemical or biologic composition to trastuzumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab
+History of allergic reactions attributed to compounds of similar chemical or biological composition as ARQ 087
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (including thalidomide), clarithromycin, or melphalan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to FLT
+Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib, cetuximab, or other agents used in the study
+Patients must not have any of the following conditions:\r\n* Recent major surgery, hormonal therapy (other than replacement) or chemotherapy, within 4 weeks prior to entering the study or those who have not recovered from the adverse events of treatment\r\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy on this trial
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy used in the study
+Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to either MLN8237 or nab-paclitaxel, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 386 or the anti-VEGF agent used in study
+History of allergic reactions attributed to 5FU, leucovorin, irinotecan or oxaliplatin or to compounds of similar chemical or biologic composition.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dexanabinol
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan or irinotecan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to black cohosh
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, irinotecan, or oxaliplatin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or abiraterone
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to fulvestrant or ganetespib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to fluorouracil (5-FU), capecitabine, oxaliplatin, leucovorin, bevacizumab, and/or vitamin D3
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to neratinib (or to capecitabine for cohorts 3a/3b)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine and hydroxychloroquine (HCQ)
+Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the study
+History of allergy or reaction attributed to compounds of chemical or biologic composition similar to those of MEDI-573 or AI
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to sonidegib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to plerixafor or bevacizumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition of BKM120, BYL719, capecitabine (including fluorouracil), trastuzumab or lapatinib
+History of allergic reactions attributed to compounds of similar chemical or biological composition to lapatinib or trastuzumab; however, patients with a history of infusion reaction to trastuzumab which was controlled with premedication on subsequent infusions without a recurring infusion reaction are eligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232
+History of allergic reactions to palbociclib or attributed to compounds of similar chemical or biologic composition to palbociclib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib maleate or olaparib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PF-00299804
+History of allergic reactions attributed to compounds similar in chemical or biological composition to vorinostat or other agents used in this study
+History of allergic reactions to compounds of similar chemical composition to the study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or other drugs formulated with polysorbate 80
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or other agents used in study
+Known or suspected allergy to any recombinant human antibodies, or compounds of similar chemical or biologic composition to sorafenib or any of the drugs in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to BMN673 (talazoparib)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ganetespib or other agents used in study; history of severe allergic or hypersensitivity reactions to taxanes
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or idarubicin or cytarabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, 5-FU, leucovorin or any of the products to be administered during dosing
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to platinums, taxanes or fluoropyrimidines
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or belinostat
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan or selinexor
+History of allergic reactions attributed to compounds of similar composition to SD-101 or ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] antibodies)
+Prior allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine (gemcitabine hydrochloride) or cisplatin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-1775 or cisplatin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib or clindamycin (topical agent for potential skin toxicity)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MEK162, anthracycline, or cytarabine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, azacitidine, mannitol, irinotecan, docetaxel, pemetrexed, or gemcitabine, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Sunphenon 90 DCF-T or other agents used in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to 3-AP (triapine) or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to tretinoin or lithium carbonate or other agents used in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 or other agents used in this study
+Subjects with history of hypersensitivity to compounds of similar chemical or biologic composition of XILONIX™.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to peg-IFN?-2b
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin and paclitaxel or other agents used in the study are excluded
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to SS1(dsFv)PE38
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide, gemcitabine or carboplatin, or other agents used in study
+ERLOTINIB HYDROCHLORIDE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib (erlotinib hydrochloride)
+SELUMETINIB ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 (selumetinib)
+AKT INHIBITOR MK2206 ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 (Akt inhibitor MK2206)
+LAPATINIB DITOSYLATE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
+SUNITINIB MALATE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to sEphB4-HSA or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MPDL3280A, carboplatin, or paclitaxel
+Patient with history of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to enzalutamide, carboplatin, or paclitaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib and/or onalespib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to onalespib or AT7519M
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or temsirolimus
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to calcitriol, ketoconazole, or other agents used in study
+Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to belinostat, including hydroxamate compounds or arginine
+Patients with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin; compounds of similar composition include auristatin PHE as an anti-fungal agent, auristatin PE (TZT-1027, Soblidotin, NSC-654663) as an anti-tumor agent and symplostatin 1 as an anti-tumor agent
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonate
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, oxaliplatin, fluorouracil (5-FU), docetaxel, or irinotecan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dinaciclib or to MK-2206
+Patients with history of allergic reactions attributed to compounds of similar composition to sirolimus, cyclophosphamide, or topotecan are not eligible
+History of allergic reactions attributed to compound of similar chemical or biologic composition to the agent(s) used in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, or nab-paclitaxel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to the agent used in study.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) or other agents used in this study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine (gemcitabine hydrochloride) or cisplatin
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or R-ICE
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MVA-brachyury-TRICOM or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanib
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan HCl for injection (propylene glycol-free), Captisol, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide, everolimus, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206
+Known hypersensitivity/history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus or fulvestrant.
+Known hypersensitivity to ipilimumab or history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Cabazitaxel, or to drugs formulated with polysorbate 80.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab
+Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to levocetirizine, capecitabine, bevacizumab, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition as TG02 citrate.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD-101 or Zevalin or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pioglitazone
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib and ipilimumab
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or AZD1775 (MK-1775) are ineligible; the AZD1775 (MK-1775) investigator brochure and the temozolomide package insert can be referenced for more information
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib and its excipients.
+Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to panitumumab
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ARQ 197 or temsirolimus
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to vemurafenib or leflunomide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, including but not limited to established allergic reaction to benzodiazepines
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to RAD001 or SOM230 (pasireotide)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents used in study (including hypersensitivity to paclitaxel, Cremophor, or platins)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or hydroxychloroquine
+The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to that of cixutumumab or to octreotide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or other agents used in the study
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to volasertib or VSLI are not eligible
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to rociletinib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to BMN 673 and AT13387 used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan, cyclophosphamide, or other agents used in the study
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed (pemetrexed disodium), 5-FU (fluorouracil), leucovorin (leucovorin calcium) or oxaliplatin, or other agents used for premedication in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, nab-paclitaxel or temozolomide
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to donepezil; hypersensitivity to donepezil
+History of allergic reaction attributed to compounds of similar chemical or biologic composition to paclitaxel, which cannot be managed by premedication
+Patients must not have a known history of allergic reactions attributed to compounds of similar chemical or biologic composition
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) and interferon-gamma; patients who are hypersensitive to Escherichia (E). coli are also excluded
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin mesylate or pembrolizumab
+History of allergic reactions attributed to tamoxifen or compounds of similar chemical or biologic composition
+Subject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
+History of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab; known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 NCI CTCAE version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to CUDC-907
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to apalutamide, abiraterone acetate, or other study drugs
+Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sildenafil or phosphodiesterase-5 (PDE5) inhibitors such as vardenafil (Levitra) and tadalafil (Cialis) are not eligible.
+Subjects with known hypersensitivity or other allergic reactions attributed to compounds of similar biologic composition to netupitant, palonosetron, dexamethasone, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to amide local anesthetics, acetaminophen or dexamethasone
+History of severe (i.e. anaphylactic) allergic reactions attributed to compounds of similar chemical or biologic composition to glucocorticoids and other component of R-
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cadaveric component, i.e. Flex HD
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel not responsive to traditional desensitization procedures
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Adriamycin, dacarbazine, or brentuximab
+History of hypersensitivity attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or osimertinib (AZD9291)
+Known sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition entinostat, nivolumab, or ipilimumab; history of severe hypersensitivity reaction to any monoclonal antibody
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to naltrexone
+No investigational agent, so no exclusion requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or device
+Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin or other agents used in the study
+Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonate
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib
+History of allergic reactions to yeast or attributed to compounds of similar chemical or biologic composition to Gardasil 9 HPV vaccine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestane
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib (Tarceva)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to 4-OHT gel
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to INO-8000 and INO-9012
+History of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to simvastatin (i.e., other statin medications)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to NeuVax
+History of allergic reaction to aspirin or attributed to compounds of similar chemical or biologic composition to aspirin, including other nonsteroidal anti-inflammatory drugs (NSAIDs)
+History of allergic reaction to zileuton or attributed to compounds of similar chemical or biologic composition to zileuton
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to MUC1/Poly?ICLC
+History of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to simvastatin (i.e., other statin medications)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to WOKVAC
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Avmacol
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to bexarotene gel, oral or topical retinoids
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Gardasil or Gardasil 9
+History of allergic reactions or intolerance attributed to aspirin or compounds of similar chemical or biologic composition
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea or EGCG
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Meriva
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of alendronate and other bisphosphonates
+Documented history of allergic reactions attributed to compounds of similar chemical or biologic composition to buproprion
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to aspirin
+Participants must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition of iloprost
+History of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to pravastatin (i.e., other statin medications)
+History of allergic reactions or hypersensitivity attributed to denosumab or any components of denosumab or compounds of similar chemical or biologic composition to denosumab, such as other RANKL inhibitors
+History of allergic reactions attributed to compounds of similar chemical composition to Polyphenon E (or green tea), or intravenous contrast that is required for CT scan
+History of allergic reactions attributed to compounds of similar chemical or biologic composition of PROSTVAC
+Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to berberine will be excluded
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to telapristone (i.e. other progesterone antagonists)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PFE
+A history of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or other agents used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Polyphenon E, tea, or any of the inactive ingredients present in the active or placebo drug products, including gelatin capsules
+History of allergic reactions attributed to compounds of similar chemical composition to the study agents
+History of allergic reactions attributed to compounds of similar chemical composition to YF476
+History of allergic reactions attributed to compounds of similar chemical or biologic composition of GARDASIL 9 (recombinant human papillomavirus nonavalent vaccine), including yeast allergy
+History of allergic reactions attributed to aspirin or compounds of similar chemical or biologic composition to the study agent
+History of allergic reactions attributed to compounds of similar chemical or biological composition to aspirin, NSAIDs, cyclooxygenase-2 (COX2) inhibitors
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabazitaxel or other drugs formulated with polysorbate 80; or abiraterone acetate
+Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) are ineligible
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to romidepsin, including cyclic tetrapeptide compounds
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to DHA or corn/soy oil in placebo agent
+History of allergic reaction to aspirin or attributed to compounds of similar chemical or biologic composition to aspirin, including other nonsteroidal anti-inflammatory drugs (NSAIDs)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to linaclotide
+Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of retinoids
+Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FES
+Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-fluorothymidine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to PBR
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or FMISO
+Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FLT or FDG are NOT eligible
+Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP
+Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FES are NOT eligible.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to demeclocycline
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in study
+SURGICAL ARM: history of allergic reactions attributed to compounds of similar chemical or biologic composition to tetracyclines
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to copper Cu 64 anti-CEA monoclonal antibody M5A (64Cu-M5A)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to magnetic resonance (MR) contrast material
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the study
+History of allergic reactions to IV contrasts or reactions attributed to compounds of similar chemical or biologic composition to Ga-68-DOTA-TOC or 18F-FLT used in study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to FDHT
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to L-[methyl-11C]methionine
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to lorlatinib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic acid (ALA)
+Women with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to isosulfan blue or indocyanine green or other agents used in this study
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to ALA; patients should refrain from use of other potential phototoxic substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts) for 72 h
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to Eovist
+History of allergic reactions to compounds of similar chemical composition to ALA
+History of allergic reaction to compounds of similar composition to ferumoxytol (e.g. IV iron)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin D
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to idelalisib
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in study
+The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or cisplatin.
+The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or carboplatin.
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, ipilimumab, or blinatumomab
+History of allergic reactions/hypersensitivity attributed to compounds of similar chemical or biologic composition to CE/BZA; (I.e. same class of drug as CE/BZA)
+History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab.